- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Labs arm invests over Rs 2 lakh in Clean Renewable Energy KK 2A
![Dr Reddys Labs arm invests over Rs 2 lakh in Clean Renewable Energy KK 2A Dr Reddys Labs arm invests over Rs 2 lakh in Clean Renewable Energy KK 2A](https://medicaldialogues.in/h-upload/2024/01/20/750x450_230651-dr-reddys-new-50.webp)
Hyderabad: Dr Reddy's Labs has announced that Aurigene Oncology Limited (''AOL'') (formerly, Aurigene Discovery Technologies Limited), a wholly-owned subsidiary of the Company has made an investment of Rs. 2,08,62,912/- in Clean Renewable Energy KK 2A Private Limited (“CREL”) and CREL has allotted 20,21,600 equity shares of Rs. 10 each at a premium of Rs. 0.32/- per share to AOL on July 31, 2024.
"The fund infused by AOL is to support the financial requirements of the CREL for the development of project.
Consequent to the said investment, AOL holds 26.99% of the share capital in CREL. The investment is done based on valuation report of an Independent Valuer and is on arm’s length basis," Dr Reddy's Labs stated.
Incorporated in 2023, Clean Renewable Energy KK 2A Private Limited, is a newly incorporated company engaged in the business of generation and distribution of power. The paid up capital of it is Rs. 7.50 Crores as on date.
Read also: Dr Reddy's Labs gets positive EMA Committee opinion for proposed Rituximab biosimilar
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Read also: Dr Reddy's Labs gets positive EMA Committee opinion for proposed Rituximab biosimilar
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751